Impact of metformin and rosiglitazone treatment on glucose transporter 4 mRNA expression in women with polycystic ovary syndrome

European Journal of Endocrinology

Volumn 158, Issue 6, 2008, Pages 793-801

  Jensterle, Mojca ^a   Janez, Andrej ^a   Mlinar, Barbara ^b   Marc, Janja ^b   Prezelj, Janez ^a   Pfeifer, Marija ^a  

^a UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

^b UNIVERSITY OF LJUBLJANA   (Slovenia)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE TRANSPORTER 4; MESSENGER RNA; METFORMIN; ROSIGLITAZONE; TESTOSTERONE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANDROGEN; ANTIDIABETIC AGENT;

ADIPOSE TISSUE; ADULT; ARTICLE; BIOPSY; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG RESPONSE; EDEMA; FEMALE; GASTROINTESTINAL SYMPTOM; GENE EXPRESSION REGULATION; HUMAN; HUMAN TISSUE; INSULIN RESISTANCE; INSULIN SENSITIVITY; MENSTRUATION; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REAL TIME POLYMERASE CHAIN REACTION; SIDE EFFECT; SIGNAL TRANSDUCTION; TESTOSTERONE BLOOD LEVEL; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; ADOLESCENT; ANALYSIS OF VARIANCE; DRUG EFFECT; GENE EXPRESSION; GENETICS; METABOLISM; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TIME;

ADOLESCENT; ADULT; ANALYSIS OF VARIANCE; ANDROGENS; FEMALE; GENE EXPRESSION; GLUCOSE TRANSPORTER TYPE 4; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; METFORMIN; POLYCYSTIC OVARY SYNDROME; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; THIAZOLIDINEDIONES; TIME FACTORS;

EID: 44949152536     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/EJE-07-0857     Document Type: Article

References (56)

1. Franks S. Polycystic ovary syndrome. New England Journal of Medicine 1995 333 853-856.
2. Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES & Yildiz BO. The prevalence and features of the polycystic ovary syndrome in an unselected population. Journal of Clinical Endocrinology and Metabolism 2004 89 2745-2749.
3. Dunaif A, Segal KR, Futterweit W & Dobrjansky A. Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes 1989 38 1165.
4. Legro RS, Finegood D & Dunaif A. A fasting glucose to insulin ratio is a useful measure of insulin sensitivity in women with polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism 1998 83 2694-2698.
5. Burchfiel CM, Curb JD, Arakaki R, Abbott RD, Sharp DS, Rodriguez BL & Yano K. Cardiovascular risk factors and hyperinsulinemia in elderly men: the Honolulu Heart Program. Annals of Epidemiology 1996 6 490-497.
6. Ferrannini E, Natali A, Bell P, Cavallo-Perin P, Lalic N & Mingrone G. Insulin resistance and hypersecretion in obesity. European Group for the Study of Insulin Resistance EGIR. Journal of Clinical Investigations 1997 100 1166-1173.
7. Bonora E, Kiechl S, Willeit J, Oberhollenzer F, Egger G, Targher G, Alberiche M, Bonadonna RC & Muggeo M. Prevalence of insulin resistance in metabolic disorders: the Bruneck Study. Diabetes 1998 47 1643-1649.
8. Dunaif A, Segal KR, Shelley DR, Green G, Dobrjansky A & Licholai T. Evidence for distinctive and intrinsic defects in insulin action in polycystic ovary syndrome. Diabetes 1992 41 1257-1266.
9. Ciaraldi TP, el Roeiy A, Madar Z, Reichart D, Olefsky JM & Yen SSC. Cellular mechanisms of insulin resistance in polycystic ovarian syndrome. Journal of Clinical Endocrinology and Metabolism 1992 75 577-583.
10. Dunaif A, Xia J, Book CB, Schenker E & Tang Z. Excessive insulin receptor serine phosphorylation in cultured fibroblasts and in skeletal muscle. A potential mechanism for insulin resistance in the polycystic ovary syndrome. Journal of Clinical Investigations 1995 96 801-810.
11. Li M, Youngren JF, Dunaif A, Goldfine ED, Maddox BA, Zhang BB & Evans JL. Decreased insulin receptor (IR) autophosphorylation in fibroblasts from patients with PCOS: effects of serine kinase inhibitors and IR activators. Journal of Clinical Endocrinology and Metabolism 2002 87 4088-4093.
12. Venkatesan AM, Dunaif A & Corbould A. Insulin resistance in polycystic ovary syndrome: progress and paradoxes. Recent Progress in Hormone Research 2001 56 295-308.
13. Rosenbaum D, Haber RS & Dunaif A. Insulin resistance in polycystic ovary syndrome: decreased expression of GLUT-4 glucose transporters in adipocytes. American Journal of Physiology 1993 264 197-202.
14. Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocrine Reviews 1997 18 774-800.
15. Ehrmann DA. Polycystic ovary syndrome. New England Journal of Medicine 2005 352 1223-1236.
16. Attia GR, Rainey WE & Carr BR. Metformin directly inhibits androgen production in human thecal cells. Fertility and Sterility 2001 76 517-524.
17. Mansfield R, Galea R, Brincat M, Hole D & Mason H. Metformin has direct effects on human ovarian steroidogenesis. Fertility and Sterility 2003 79 956-962.
18. Nawrocka J & Starczewski A. Effects of metformin treatment in women with polycystic ovary syndrome depends on insulin resistance. Gynecological Endocrinology 2007 23 231-237.
19. Harborne L, Fleming R, Lyall H, Norman J & Sattar N. Descriptive review of the evidence for the use of metformin in polycystic ovary syndrome. Lancet 2003 361 1894-1901.
20. Lord JM, Flinght IH & Norman RJ. Metformin in polycystic ovary syndrome: systematic review and meta-analysis. BMI 2003 327 951-953.
21. Legro RS, Barnhart HX, Schlaff WD, Carr BR, Diamond MP, Carson SA, Steinkampf MP, Coutifaris C, McGovern PG, Cataldo NA, Gosman GG, Nestler JE, Giudice LC, Leppert PC & Myers ER. Cooperative Multicenter Reproductive Medicine Network. Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome. New England Journal of Medicine 2007 356 551-566.
22. Costello MF, Shrestha B, Eden J, Johnson NP & Sjoblom P. Metformin versus oral contraceptive pill in polycystic ovary syndrome: a Cochrane review. Human Reproduction 2007 22 1200-1209.
23. Harborne L, Fleming R, Lyall H, Sattar N & Norman J. Metformin or antiandrogen in the treatment of hirsutism in polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism 2003 88 4116-4123.
24. Harborne LR, Sattar N, Norman JE & Fleming R. Metformin and weight loss in obese women with polycystic ovary syndrome: comparison of doses. Journal of Clinical Endocrinology and Metabolism 2005 90 4593-4598.
25. Tang T, Glanville J, Hayden CJ, White D, Barth JH & Balen AH. Combined lifestyle modification and metformin in obese patients with polycystic ovary syndrome. A randomized, placebo-controlled, double-blind multicentre study. Human Reproduction 2006 21 80-89.
26. Banaszewska B, Duleba AJ, Spaczynski RZ & Pawelczyk L. Lipids in polycystic ovary syndrome: role of hyperinsulinemia and effects of metformin. American Journal of Obstetrics and Gynaecology 2006 194 1266-1272.
27. Arner P. Free fatty acids - do they play a central role in type 2 diabetes? Diabetes, Obesity and Metabolism 2001 3 S11-S19.
28. Lebovitz HE & Banerji MA. Insulin resistance and its treatment by thiazolidinediones. Recent Progress in Hormone Research 2001 56 265-294.
29. Mori Y, Murakawa Y, Okada K, Horikoshi H, Yokoyama J, Tajima N & Ikeda Y. Effect of troglitazone on body fat distribution in type 2 diabetic patients. Diabetes Care 1999 22 908-912.
30. Mitwally MF, Witchel SF & Casper RF. Troglitazone: a possible modulator of ovarian steroidogenesis. Journal of the Society for Gynecologic Investigations 2002 9 163-167.
31. Pasquali R. The endocrine of obesity in eumenorrheic women. In Androgen Excess Disorders in Women, pp 507-518. Eds R Azziz, JE Nestler & D Dewailly, Philadelphia: Lippincott- Raven Publishers, 1997.
32. Dunaif A, Scott D, Finegood D, Quintana B & Whitcomb R. The insulin-sensitizing agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism 1996 81 3299-3306.
33. Azziz R, Ehrmann D, Legro RS, Whitcomb RW, Hanley R, Fereshetian AG, O'Keefe M & Ghazzi MN. PCOS/Troglitazone Study Group. Troglitazone improves ovulation and hirsutism in the potycystic ovary syndrome: a multicenter, double blind, placebo-controlled trial. Journal of Clinical Endocrinology and Metabolism 2001 86 1626-1632.
34. Azziz R, Ehrmann DA, Legro RS, Fereshetian AG, O'Keefe M & Ghazzi MN. PCOS/Troglitazone Study Group. Troglitazone decreases adrenal androgen levels in women with polycystic ovary syndrome. Fertility and Sterility 2003 79 932-937.
35. Cataldo NA, Abbasi F, McLaughlin TL, Lamendola C & Reaven GM. Improvement in insulin sensitivity followed by ovulation and pregnancy in a woman with polycystic ovary syndrome who was treated with rosiglitazone. Fertility and Sterility 2001 76 1057-1059.
36. Ghazeeri G, Kutteh WH, Bryer-Ash M, Haas D & Ke RW. Effect of rosiglitazone on spontaneous and clomiphene citrate-induced ovulation in women with polycystic ovary syndrome. Fertility and Sterility 2003 79 562-566.
37. Sepilian V & Nagamani M. Effects of rosiglitazone in obese women with polycystic ovary syndrome and severe insulin resistance. Journal of Clinical Endocrinology and Metabolism 2005 90 60-65.
38. Cataldo NA, Abbasi F, McLaughlin TL, Basina M, Fechner PY, Giudice LC & Reaven GM. Metabolic and ovarian effects of rosiglitazone treatment for 12 weeks in insulin-resistant women with polycystic ovary syndrome. Human Reproduction 2006 21 109-120.
39. Rautio K, Tapanainen JS, Ruokonen A & Morin-Papunen LC. Endocrine and metabolic effects of rosiglitazone in overweight women with PCOS: a randomized placebo-controlled study. Human Reproduction 2006 21 1400-1407.
40. Majuri A, Santaniemi M, Rautio K, Kunnari A, Vartiainen J, Ruokonen A, Kesaniemi YA, Tapanainenm JS, Ukkola O & Morin-Papunen L. Rosiglitazone treatment increases plasma levels of adiponectin and decreases levels of resistin in overweight women with PCOS: a randomized placebo-controlled study. European Journal of Endocrinology 2007 156 263-269.
41. Zawadzki JK & Dunaif A. Diagnostic criteria for polycystic ovary syndrome. In Polycystic Ovary Syndrome, pp 377-384. Eds A Dunaif, F Haseltine & GR Merriam, Boston: Blackwell Scientific Publications, 1992.
42. Azziz R. Definition, diagnosis, and epidemiology of the polycystic ovary syndrome. In The Polycystic Ovary Syndrome: Current Concepts on Pathogenesis and Clinical Care, p 5. Ed. R Azziz, New York: Springer Science + Business Media, LCC, 2007.
43. Mavri A, Alessi MC, Bastelica D, Geel-Georgelin O, Fina F, Sentocnik IT, Stegnar M & Juhan-Vague I. Subcutaneous abdominal, but not femoral fat expression of plasminogen activator inhibitor-1 (PAI-I) is related to plasma PAI-1 levels and insulin resistance and decreases after weight loss. Diabetologia 2001 44 2025-2031.
44. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF & Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985 28 412-419.
45. Hedblad B, Nilsson P, Janzon L & Berglund G. Relation between insulin resistance and carotid intima-media thickness and stenosis in non-diabetic subjects. Results from a cross-sectional study in Malmo, Sweden. Diabetic Medicine 2000 17 299-307.
46. Baillargeon JP, Jakubowicz DJ, Iuorno MJ, Jakubowicz S & Nestler JE. Effects of metformin and rosiglitazone, alone and in combination, in nonobese women with polycystic ovary syndrome and normal indices of insulin sensitivity. Fertility and Sterility 2004 82893-902.
47. Mitkov M, Pehlivanov B & Terzieva D. Metformin versus rosiglitazone in the treatment of polycystic ovary syndrome. European Journal of Obstetrics Gynaecology and Reproductive Biology 2006 126 93-98.
48. Legro RS, Zaino RJ, Demers LM, Kunselman AR, Gnatuk CL, Williams NI & Dodson WC. The effects of metformin and rosiglitazone, alone and in combination, on the ovary and endometrium in polycystic ovary syndrome. American Journal of Obstetrics and Gynaecology 2007 196 402.
49. Pillai A, Bang H & Green C. Metformin and glitazones: do they really help PCOS patients? Journal of Family Practice 2007 56 444-453.
50. Furnsinn C, Nowotny P, Brunmair B, Gras F, Roden M, Waldhäusl W & Vierhapper H. Thiazolidinediones influence plasma steroids of male obese Zucker rats. Endocrinology 2002 143 327.
51. Vierhapper H, Nowomy P & Waldhausl W. Reduced production rates of testosterone and dihydrotestosterone in healthy men treated with rosiglitazone. Metabolism 2003 52 230-232.
52. Gasic S, Nagarmani M, Green A & Urban RJ. Troglitazone is a competitive inhibitor of 39-hydroxysteroid dehydrogenase enzyme in the ovary. American Journal of Obstetrics and Gynaecology 2001 184 575-579.
53. Mu YM, Yanase T, Nishi Y, Waseda N, Oda T, Tanaka A, Takayanagi R & Nawata H. Insulin sensitizer, troglitazone, directly inhibits aromatase activity in human ovarian granulosa cells. Biochemical and Biophysical Research Communications 2000 271 710-713.
54. Arlt W Auchus RJ & Miller WL. Thiazolidinediones but not metformin directly inhibit the steroidogenic enzymes P450c17 and 39-hydroxysteroid dohydrogenase. Journal of Biological Chemistry 2001 276 16767-16771.
55. la Marca A, Egbe TO, Morgante G, Paglia T, Cianci A & De Leo V Metformin treatment reduces ovarian cytochrome P-450c17alpha response to human chorionic gonadotrophin in women with insulin resistance-related polycystic ovary syndrome. Human Reproduction 2000 15 21-23.
56. Balen A. Strategies for ovulation induction in the management of anovulatory polycystic ovary syndrome. In The Polycystic Ovary Syndrome: Current Concepts on Pathogenesis and Clinical Care, p 110. Ed. R Azziz, New York: Springer Science + Business Media, LCC, 2007.